Chilton Capital Management’s ResMed RMD Stock Holding History

Chilton Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$482	–	729
2025 Q4	$482	Buy	+2	New	+$511	﹤0.01%	641

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chilton Capital Management's RMD Position: Q1 2026 in Review

Chilton Capital Management sold out of ResMed (RMD) in Q1 2026, closing a stake of 2 shares — an estimated $482 sold.

Chilton Capital Management first reported a position in RMD in Q4 2025 and held it in 1 quarter. The position peaked at $482 in Q4 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Chilton Capital Management reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
Chilton Capital Management sold 2 ResMed shares in Q1 2026, an estimated $482.
Chilton Capital Management first reported a position in ResMed in Q4 2025 and held it in 1 quarter.
Chilton Capital Management's ResMed position peaked at $482 in Q4 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Chilton Capital Management's 13F filing for Q1 2026, filed 11 May 2026.